{"id":145801,"date":"2025-03-06T11:08:35","date_gmt":"2025-03-06T05:38:35","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=145801"},"modified":"2025-03-06T14:45:52","modified_gmt":"2025-03-06T09:15:52","slug":"pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/","title":{"rendered":"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3900651397\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2767988565\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price action<\/strong><\/h2><p>With a market capitalization of Rs. 92,246.50 Crores on Thursday, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/ZYDUSLIFE\" target=\"_blank\" rel=\"noreferrer noopener\">Zydus Lifesciences Ltd<\/a><\/strong> jumped upto 6.8 percent after making a high of Rs. 947.95 compared to its previous closing price of Rs. 887.55.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened&nbsp;<\/strong><\/h2><p><strong>Zydus Lifesciences <\/strong>engaged in developing, manufacturing, and marketing a wide range of pharmaceuticals has received final approval from the USFDA to manufacture Dasatinib Tablets in various strengths (20 mg to 140 mg). These tablets are used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).<\/p><p>The tablets will be produced at Zydus&#8217; SEZ facility in Ahmedabad, and this Dasatinib tablet had annual sales of $1.8 billion in the US as of January 2025. This approval brings Zydus&#8217; total number of approvals to 415, with 483 ANDA filings since FY 2003-04.<\/p><div class=\"trade-content_5\" id=\"trade-3505388971\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>About the company<\/strong><\/h2><p>Zydus Lifesciences Ltd is a leading global healthcare company based in India, primarily focused on developing, manufacturing, and marketing a wide range of pharmaceuticals, including generics, active pharmaceutical ingredients (APIs), and consumer wellness products.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Key Highlights (Q3 FY25)<\/strong><\/h2><p>India&#8217;s formulation business grew faster than the market, driven by strong chronic outperformance with secondary sales growth of 8 percent according to IQVIA. The Consumer Wellness business grew in double digits, supported by robust volume growth of 4.8 percent despite a muted demand scenario in the industry.<\/p><p>The U.S. formulations business continued its upward trajectory, with impressive year-on-year growth driven by volume expansion and new launches over the past 12 months. The international markets business grew in double digits, supported by healthy demand across various markets.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Business-wise sales Breakup<\/strong><\/h2><p>The company generates 29 percent of its product sales from India Formulations, amounting to Rs. 1489.3 crore, the Consumer Wellness segment contributes 9 percent which is 461.1 crore, U.S market generates 47 percent totaling Rs. 2407.9 crore, and international Formulations contribute 11 percent of Rs. 563.6 crores, API segment 3 percent which is Rs. 153.7 crores, and lastly, alliances contribute 1 percent amounting to Rs.51.2 crores of the total sales of 5,123.5 crores.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Sridhar J<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-content-10\" id=\"trade-274561264\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"trade-after-content\" id=\"trade-170253983\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg). Price action With a market capitalization of Rs. 92,246.50 Crores on Thursday, the shares of Zydus [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":125304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[4865,31,13525],"tags":[],"class_list":["post-145801","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-news","category-stock-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets\" \/>\n<meta property=\"og:description\" content=\"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-06T05:38:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-06T09:15:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/\",\"name\":\"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"datePublished\":\"2025-03-06T05:38:35+00:00\",\"dateModified\":\"2025-03-06T09:15:52+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets - Trade Brains Features","description":"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets","og_description":"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-06T05:38:35+00:00","article_modified_time":"2025-03-06T09:15:52+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/","name":"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","datePublished":"2025-03-06T05:38:35+00:00","dateModified":"2025-03-06T09:15:52+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the pharmaceuticals company specializing in developing, manufacturing, and marketing a wide range of pharmaceuticals jumped upto 7 percent upon receiving approval from the USFDA to manufacture Dasatinib tablets in various strengths (20 mg to 140 mg).","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-7-after-receiving-usfda-approval-to-manufacture-dasatinib-tablets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 7%\u00a0after receiving USFDA approval to manufacture Dasatinib tablets"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=145801"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145801\/revisions"}],"predecessor-version":[{"id":145802,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/145801\/revisions\/145802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/125304"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=145801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=145801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=145801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}